Tempest Therapeutics Stock Performance
| TPST Stock | USD 2.61 0.03 1.16% |
The entity has a beta of 0.83, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Tempest Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Tempest Therapeutics is expected to be smaller as well. At this point, Tempest Therapeutics has a negative expected return of -1.85%. Please make sure to validate Tempest Therapeutics' jensen alpha, kurtosis, as well as the relationship between the Kurtosis and price action indicator , to decide if Tempest Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Tempest Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in February 2026. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
Actual Historical Performance (%)
One Day Return 1.16 | Five Day Return (2.25) | Year To Date Return (11.53) | Ten Year Return (99.87) | All Time Return (99.85) |
Last Split Factor 1:13 | Dividend Date 2018-12-10 | Last Split Date 2025-04-09 |
1 | Why Tempest Therapeutics Inc. stock appeals to dividend seekers - Market Performance Report Daily Stock Momentum Reports - newser.com | 11/06/2025 |
2 | Is Tempest Therapeutics Inc. stock entering bullish territory - Portfolio Growth Summary Real-Time Sentiment Analysis - newser.com | 11/10/2025 |
3 | Is Tempest Therapeutics Inc. stock poised for growth - July 2025 Momentum AI Powered Market Trend Analysis - newser.com | 11/13/2025 |
4 | Why Tempest Therapeutics Stock Is Down 45 percent Today | 11/19/2025 |
5 | Acquisition by Justin Trojanowski of 30000 shares of Tempest Therapeutics at 0.86 subject to Rule 16b-3 | 11/21/2025 |
6 | Tempest Announces Up To 8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq R... | 11/25/2025 |
7 | Tempest Announces Closing of Up To 8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Und... | 11/26/2025 |
8 | Acquisition by Woiwode Thomas of 3500 shares of Tempest Therapeutics subject to Rule 16b-3 | 11/28/2025 |
9 | Market Outlook Will Tempest Therapeutics Inc stock pay special dividends - July 2025 Drop Watch Real-Time Buy Signal Alerts - moha.gov.vn | 12/29/2025 |
10 | Insider Trading | 01/09/2026 |
| Begin Period Cash Flow | 39.7 M | |
| Total Cashflows From Investing Activities | -435 K |
Tempest Therapeutics Relative Risk vs. Return Landscape
If you would invest 1,068 in Tempest Therapeutics on October 24, 2025 and sell it today you would lose (807.00) from holding Tempest Therapeutics or give up 75.56% of portfolio value over 90 days. Tempest Therapeutics is currently does not generate positive expected returns and assumes 8.6018% risk (volatility on return distribution) over the 90 days horizon. In different words, 77% of stocks are less volatile than Tempest, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Tempest Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Tempest Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Tempest Therapeutics, and traders can use it to determine the average amount a Tempest Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2152
| High Returns | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | TPST |
Based on monthly moving average Tempest Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Tempest Therapeutics by adding Tempest Therapeutics to a well-diversified portfolio.
Tempest Therapeutics Fundamentals Growth
Tempest Stock prices reflect investors' perceptions of the future prospects and financial health of Tempest Therapeutics, and Tempest Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Tempest Stock performance.
| Return On Equity | -4.05 | ||||
| Return On Asset | -0.89 | ||||
| Current Valuation | 13.6 M | ||||
| Shares Outstanding | 4.93 M | ||||
| Price To Earning | 0.23 X | ||||
| Price To Book | 2.00 X | ||||
| EBITDA | (40.14 M) | ||||
| Net Income | (41.84 M) | ||||
| Cash And Equivalents | 51.62 M | ||||
| Cash Per Share | 4.95 X | ||||
| Total Debt | 15.37 M | ||||
| Debt To Equity | 0.49 % | ||||
| Current Ratio | 3.05 X | ||||
| Book Value Per Share | 1.43 X | ||||
| Cash Flow From Operations | (33.03 M) | ||||
| Earnings Per Share | (9.73) X | ||||
| Market Capitalization | 12.71 M | ||||
| Total Asset | 41.49 M | ||||
| Retained Earnings | (207.11 M) | ||||
| Working Capital | 17.25 M | ||||
About Tempest Therapeutics Performance
Assessing Tempest Therapeutics' fundamental ratios provides investors with valuable insights into Tempest Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Tempest Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.16) | (1.22) | |
| Return On Capital Employed | (1.77) | (1.68) | |
| Return On Assets | (1.16) | (1.22) | |
| Return On Equity | (1.97) | (2.07) |
Things to note about Tempest Therapeutics performance evaluation
Checking the ongoing alerts about Tempest Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Tempest Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Tempest Therapeutics generated a negative expected return over the last 90 days | |
| Tempest Therapeutics has high historical volatility and very poor performance | |
| Tempest Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (41.84 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Tempest Therapeutics currently holds about 51.62 M in cash with (33.03 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.95, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from thelincolnianonline.com: BioAtla, Inc. Short Interest Down 29.9 percent in December |
- Analyzing Tempest Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Tempest Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Tempest Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Tempest Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Tempest Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Tempest Therapeutics' stock. These opinions can provide insight into Tempest Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Tempest Stock Analysis
When running Tempest Therapeutics' price analysis, check to measure Tempest Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tempest Therapeutics is operating at the current time. Most of Tempest Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tempest Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tempest Therapeutics' price. Additionally, you may evaluate how the addition of Tempest Therapeutics to your portfolios can decrease your overall portfolio volatility.